Maria C Bell - American College of Obstetricians and Gynecologists, Sanford Health

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 27 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy with or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors

JOURNAL OF CLINICAL ONCOLOGYno. 3 (2025)

Cited0Views0WOSBibtex

OVATION-2: A Randomized Phase I/II Study Evaluating the Safety and Efficacy of IMNN-001 (IL-12 Gene Therapy) with Neo/adjuvant Chemotherapy in Patients Newly-Diagnosed with Advanced Epithelial Ovarian Cancer

Premal H Thaker,Debra L Richardson,Andrea R Hagemann,Robert W Holloway,Mark Reed, Melanie K Bergman,Bhavana Pothuri, Stephen DePasquale, Jennifer M Scalici, Amy J Bregar, Christopher J Darus, Karen Finkelstein, Charles A Leath,Maria Bell, David P Warshal,Richy Agajanian, Megan D Indermaur,Alberto A Mendivil, Diane M Provencher, Lee-Jen Wei, Nicholas Borys,Lauren Musso, Stacy R Lindborg, Douglas V Faller,Khursheed Anwer,William H Bradley

Gynecologic oncology (2025): 182-191

Cited0Views0WOSBibtex

Abstract CT267: Temsirolimus (T) in Patients (pts) with Solid Tumors with AKT1/3 Amplification (amp) or Mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Deepti Behl,Michael Rothe,Pam K. Mangat,Elizabeth Garrett-Mayer, Niklas Mackler,Herbert L. Duvivier,Philip J. Gold,Sapna R. Patel, Regan M. Duffy, Lauren A. Mauro,Eugene R. Ahn,Maria Bell,Carmen J. Calfa,Jean L. Grem,Jens Rueter,Margaret von Mehren,Gina N. Grantham,Abigail Gregory,Dominique C. Hinshaw,Susan Halabi,Richard L. Schilsky

Cancer Researchno. 7_Supplement (2024)

Cited0Views0Bibtex

Temsirolimus (T) in Patients (pts) with Solid Tumors with AKT1/3 Amplification (amp) or Mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

CANCER RESEARCHno. 7 (2024)

Cited0Views0Bibtex

Nivolumab Plus Ipilimumab (N+I) in Patients (pts) with Solid Tumors with High Tumor Mutational Burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

John K. Chan,Michael Rothe,Pam K. Mangat,Elizabeth Garrett-Mayer,Timothy Lewis Cannon,Eugene R. Ahn,Paul Swiecicki,Evthokia Hobbs,Reza Nazemzadeh,Maria C. Bell,Peter Joel Hosein,Funda Meric-Bernstam,Dominique C. Hinshaw,Abby Gregory,Gina N. Grantham,Susan Halabi,Richard L. Schilsky

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

Cited0Views0Bibtex

Abstract CT046: A Randomized, Phase 2 Study of Pembrolizumab Plus Chemotherapy with or Without Anti—immunoglobulin-Like Transcript 4 Monoclonal Antibody MK-4830 As Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer

Jung-Yun Lee,Maria Bell,Mariusz Bidzinski,Lubomir Bodnar,Jack Junjie Chan, Marta Gill-Martin,Carolina Ibanez,Domenica Lorusso,Chien-Hsing Lu,Ora Rosengarten,Steven M. Townson,Julie Kobie,Yiwei Zhang,Scott Pruitt,Ronnie Shapira-Frommer

Cancer Researchno. 8_Supplement (2023)

Cited0Views0Bibtex

A Randomized, Phase 2 Study of Pembrolizumab Plus Chemotherapy with or Without Anti-Immunoglobulin-like Transcript 4 Monoclonal Antibody MK-4830 As Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer

CANCER RESEARCHno. 8 (2023)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn